Optimizing Palliative Management For End-of-Life Elderly Patient With Non-Hodgkin Lymphoma : A Case Report
DOI:
https://doi.org/10.51601/ijhp.v6i1.518Abstract
Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL) in the elderly population. DLBCL is potentially curable with immunochemotherapy but becomes more difficult to cure as patients get older leading to poor prognosis. Palliative care is essential for patients with this condition to relieve their suffering and improve their quality of life. Treatment strategies of DLBCL in elderly patients remain a challenge for physicians and the patients. An 87-year-old male presented with difficulty swallowing for the past four months, worsened since last week. Throat pain, obstruction sensation, and confined to bed due to weakness. The patient has been diagnosed with DLBCL and refused chemotherapy. Dark-colored residue was observed in the nasogastric tube. There is an enlargement of right cervical lymph-node. His laboratory workup shows Hb 8,9mg/dL, histopathological of the oropharyngeal tissue showed Diffuse Large B-Cell Lymphoma, activated B-Cell subtype. Patient was treated through multidisciplinary approach to improve overall condition and his quality of life. The management of elderly patients with DLBCL requires multidisciplinary approach that considers patient preferences and quality of life. Elderly Prognostic Index are needed to evaluate patient condition, prognosis, and guide therapeutic decisions. Palliative therapy is an approach aimed at improving the quality of life of patients facing life-threatening illness through early identification and comprehensive management of pain, physical, psychosocial, and spiritual problems. Management of DLBCL in elderly patients requires balancing risks and benefits considering frailty, comorbidities, and overall functional status. Regardless of therapeutic choice, palliative and supportive care should be provided through a multidisciplinary approach to relieve suffering and preserve quality of life. Treatment decisions should be made involving the patient and their family, focusing on the ultimate goals of care in accordance to their wishes.
Downloads
References
[1] Cong Ma et al., “Non-Hodgkin’s lymphoma in an elderly patient with renal dysfunction: a case report,” J. Int. Med. Res., vol. 48, no. 8, p. 0300060520945858, Aug. 2020, doi: 10.1177/0300060520945858.
[2] E. C. Ayers and S. M. Smith, “Diffuse Large B-Cell Lymphoma in the Older and Frail Patient,” Cancers, vol. 17, no. 5. p. 885, 2025. doi: 10.3390/cancers17050885.
[3] A. Tucci et al., “Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL).,” Haematologica, vol. 108, no. 4, pp. 1083–1091, Apr. 2023.
[4] M. Di, S. F. Huntington, and A. J. Olszewski, “Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients,” Oncologist, vol. 26, no. 2, pp. 120–132, Feb. 2021.
[5] B. Amoozgar and B. S. Kahl, “Initial treatment of elderly population with aggressive lymphoma: a narrative review of current evidence and future directions,” Ann. Lymphoma, vol. 6, no. 9, 2022, doi: 10.21037/aol-22-9.
[6] F. Merli, S. Pozzi, H. Catellani, E. Barbieri, and S. Luminari, “The Role of Geriatric Assessment in the Management of Diffuse Large B-Cell Lymphoma,” Cancers, vol. 15, no. 24. 2023. 10.3390/cancers15245845.
[7] P. J. Lugtenburg, A. R. Lyon, R. Marks, and S. Luminari, “Treatment of Aggressive Non-Hodgkin’S Lymphoma In Frail Patients: Cardiac Comorbidities and Advanced Age,” Futur. Oncol., vol. 15, no. 11, pp. 1197–1205, Feb. 2019, doi: 10.2217/fon-2019-0019.
[8] G. B. Crawford et al., “Care of the adult cancer patient at the end of life: ESMO Clinical Practice Guidelines☆,” ESMO Open, vol. 6, no. 4, p. 100225, 2021, doi: https://doi.org/10.1016/j.esmoop.2021.100225.
[9] O. O. Odejide, “Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas,” Hematology, vol. 2020, no. 1, pp. 148–153, Dec. 2020, doi: 10.1182/hematology.2020000100.
[10] A. Arcari, F. Cavallo, B. Puccini, and D. Vallisa, “New treatment options in elderly patients with Diffuse Large B-cell Lymphoma.,” Front. Oncol., vol. 13, p. 1214026, 2023, doi: 10.3389/fonc.2023.1214026.
[11] T. A. Eyre et al., “Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆,” Ann. Oncol., vol. 36, no. 11, pp. 1263–1284, 2025, doi: https://doi.org/10.1016/j.annonc.2025.07.014.
[12] F. Merli et al., “Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi,” J. Clin. Oncol., vol. 39, no. 11, pp. 1214–1222, Feb. 2021, doi: 10.1200/JCO.20.02465.
[13] V. Goede, “Frailty and Cancer: Current Perspectives on Assessment and Monitoring,” Clin. Interv. Aging, vol. 18, no. null, pp. 505–521, Dec. 2023, doi: 10.2147/CIA.S365494.
[14] M. Aapro et al., “Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines††FootnotesApproved by the ESMO Guidelines Committee: October 2017.,” Ann. Oncol., vol. 29, pp. iv96–iv110, 2018, doi: https://doi.org/10.1093/annonc/mdx758.
[15] G. H. Lyman et al., “American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer,” Blood Adv., vol. 5, no. 4, pp. 927–974, Feb. 2021, doi: 10.1182/bloodadvances.2020003442.
[16] D. Arakaki, M. Iwata, and T. Terasawa, “External validation and update of the International Medical Prevention Registry on Venous Thromboembolism bleeding risk score for predicting bleeding in acutely ill hospitalized medical patients: a retrospective single-center cohort study in Japan,” Thromb. J., vol. 22, no. 1, p. 31, 2024.
[17] M. Muscaritoli et al., “ESPEN practical guideline: Clinical Nutrition in cancer.,” Clin. Nutr., vol. 40, no. 5, pp. 2898–2913, May 2021, doi: 10.1016/j.clnu.2021.02.005.
[18] F. Massaro, F. Andreozzi, C. Vandevoorde, and D. Bron, “Supportive Care in Older Lymphoma Patients to Reduce Toxicity and Preserve Quality of Life,” Cancers, vol. 15, no. 22. 2023. doi: 10.3390/cancers15225381.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Steven Jonathan, Devina Ravelia Tiffany Subroto, I Putu Bayu Triguna
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
